1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 58:71–96. 2008.
|
3
|
Conlon KC, Klimstra DS and Brennan MF:
Long-term survival after curative resection for pancreatic ductal
adenocarcinoma. Clinico-pathologic analysis of 5-year survivors.
Ann Surg. 223:273–279. 1996.PubMed/NCBI
|
4
|
Matsuno S, Egawa S, Fukuyama S, et al:
Pancreatic cancer registry in Japan: 20 years of experience.
Pancreas. 28:219–230. 2004.PubMed/NCBI
|
5
|
Kayahara M, Nagakawa T, Ueno K, et al: An
evaluation of radical resection for pancreatic cancer based on the
mode of recurrence as determined by autopsy and diagnostic imaging.
Cancer. 72:2118–2123. 1993. View Article : Google Scholar : PubMed/NCBI
|
6
|
Burris HA, Moore MJ, Andersen J, et al:
Improvements in survival and clinical benefit with gemcitabine as
first-line therapy for patients with advanced pancreatic cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
7
|
Ottle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs observation in patients
undergoing curative-intent resection of pancreatic cancer: a
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
|
8
|
Golcher H, Brunner T, Grabenbauer G, et
al: Preoperative chemo-radiation in adenocarcinoma of the pancreas.
A single centre experience advocating a new treatment strategy.
EJSO. 34:756–764. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Goses MJ, Dressen RC, Rutten HJ, et al:
Prepoerative radio-chemotherapy is successful also in patients with
locally advanced rectal cancer who have intrinsically high
apoptotic tumors. Ann Oncol. 19:2026–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Yang AD, Fan F, Camp ER, et al: Chronic
oxaliplatin resistance induces epithelial-mesenchymal transition in
colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Tsukamoto H, Shibata K, Kajiyama H, et al:
Irradiation-induced epithelial-mesencymal transition (EMT) related
to invasive potential in endometrial carcinoma cells. Gynecol
Oncol. 107:500–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Tajima H, Ohta T, Shoji Y, et al:
Expression of epithelial-mesenchymal transition markers in locally
recurrent hepatocellular carcinoma after radiofrequency ablation.
Exp Therap Med. 1:347–350. 2010. View Article : Google Scholar
|
13
|
Shah AN, Summy JM, Zhang J, Park SI,
Darikh NU and Gallick GE: Development and characterization of
gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yang J, Mani SA, Donaher JL, et al: Twist,
a master regulator of morphogenesis, plays an essential role in
tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hay ED and Zuk A: Transformations between
epithelium and mesenchyme: normal, pathological and experimentally
induced. Am J Kidney Dis. 26:678–690. 1995. View Article : Google Scholar : PubMed/NCBI
|
16
|
Thiery JP: Epithelial-mesenchymal
transitions in tumor progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
18
|
Kikuta K, Masamune A, Watanabe T, et al:
Pancreatic stellate cells promote epithelial-mesenchymal transition
in pancreatic cancer cells. Biochem Biophys Res Commun.
403:380–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Evans DB, Rich TA, Byrd DR, et al:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Dive C, Smith RA, Garner E, et al:
Considerations for the use of plasma cytokeratin 18 as a biomarker
in pancreatic cancer. Br J Cancer. 102:577–582. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Du Z, Qin R, Wei C, et al: Pancreatic
cancer cells resistant to chemoradiotherapy rich in
‘stem-cell-like’ tumor cells. Dig Dis Sci. 10:741–750.
2010.PubMed/NCBI
|
22
|
Hong SP, Wen J, Bang S, Park S and Song
SY: CD44-positive cells are responsible for gemcitabine resistance
in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Müerköster SS, Werbing V, Koch D, et al:
Role of myofibroblasts in innate chemoresistance of pancreatic
carcinoma – epigenetic downregulation of caspase. Int J Cancer.
123:1751–1760. 2008.PubMed/NCBI
|
24
|
Yin T, Wang C, Liu T, Zhao G, Zha Y and
Yang M: Expression of Snail in pancreatic cancer promotes
metastasis and chemoresistsance. J Surg Res. 141:196–203. 2007.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Cauffert B, Mornex F, Bonnetain F, et al:
Phase III trial comparing intensive induction chemoradiotherapy (60
Gy, infusional 5-FU and intermittent cicplatin) followed by
maintenance gemcitabine with gemcitabine alone for locally advanced
unresectable pancreatic cancer. Definitive results of the 2000-01
FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008.
|
26
|
Van Laethem JL, Hammel P, Mornex F, et al:
Adjuvant gemcitabine alone versus gemcitabine-based
chemoradiotherapy after curative resection for pancreatic cancer: a
randomized EORTC-40013-22012 /FFCD-9203/GERCOR phase II study. J
Clin Oncol. 28:4450–4456. 2010.
|